【视频】睿智医药董事长胡瑞连：深耕创新药智造 打造医药CXO服务新标杆

Core Insights - The company has been focusing on innovation in the CXO (Contract Research Organization and Contract Development and Manufacturing Organization) sector since the appointment of Hu Ruilian as Chairman and CEO [1] - The company has developed a comprehensive service system that includes target discovery, process development, preclinical research, commercial production, and global submission, leveraging its core capabilities in CRO and CDMO [1] - The business scope has expanded to include new modalities such as ADC/XDC (Antibody-Drug Conjugates/Antibody-Drug Conjugates), small nucleic acids, and peptides, as well as chemical and biological drugs, forming a global R&D and production service network [1] Industry Trends - The pharmaceutical R&D outsourcing industry is entering a new development phase, driven by advancements in innovative drug development towards new modalities and the deep integration of AI technology with drug manufacturing [3]